CASE REPORT article
Case Report: Stepwise Anti-Inflammatory and Anti-SARS-CoV-2 Effects Following Convalescent Plasma Therapy With Full Clinical Recovery
- 1Department of Internal Medicine, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
- 2Medical Education Unit, School of Medicine, Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland
- 3Division of Immunology and Allergy, Department of Medicine, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
- 4Laboratory of Virology and Geneva Centre for Emerging Viral Diseases, Geneva University Hospitals and Faculty of Medicine, University of Geneva, Geneva, Switzerland
- 5Department of Radiology and Interventional Radiology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
- 6Institute of Microbiology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
- 7Regional Blood Transfusion Service, Swiss Red Cross (SRC), Basel, Switzerland
- 8Interregional Blood Transfusion SRC, Epalinges, Switzerland
- 9Department of Geriatric Medicine and Geriatric Rehabilitation, Lausanne University Hospital, Lausanne, Switzerland
- 10Division of Hematology, Department of Oncology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
- 11Department of Respiratory Disease, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
- 12Division of Infectious Diseases, Department of Medicine, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
- 13Department of Oncology, Lausanne University Hospital and University of Lausanne, Epalinges, Switzerland
In these times of COVID-19 pandemic, concern has been raised about the potential effects of SARS-CoV-2 infection on immunocompromised patients, particularly on those receiving B-cell depleting agents and having therefore a severely depressed humoral response. Convalescent plasma can be a therapeutic option for these patients. Understanding the underlying mechanisms of convalescent plasma is crucial to optimize such therapeutic approach. Here, we describe a COVID-19 patient who was deeply immunosuppressed following rituximab (anti-CD20 monoclonal antibody) and concomitant chemotherapy for chronic lymphoid leukemia. His long-term severe T and B cell lymphopenia allowed to evaluate the treatment effects of convalescent plasma. Therapeutic outcome was monitored at the clinical, biological and radiological level. Moreover, anti-SARS-CoV-2 antibody titers (IgM, IgG and IgA) and neutralizing activity were assessed over time before and after plasma transfusions, alongside to SARS-CoV-2 RNA quantification and virus isolation from the upper respiratory tract. Already after the first cycle of plasma transfusion, the patient experienced rapid improvement of pneumonia, inflammation and blood cell counts, which may be related to the immunomodulatory properties of plasma. Subsequently, the cumulative increase in anti-SARS-CoV-2 neutralizing antibodies due to the three additional plasma transfusions was associated with progressive and finally complete viral clearance, resulting in full clinical recovery. In this case-report, administration of convalescent plasma revealed a stepwise effect with an initial and rapid anti-inflammatory activity followed by the progressive SARS-CoV-2 clearance. These data have potential implications for a more extended use of convalescent plasma and future monoclonal antibodies in the treatment of immunosuppressed COVID-19 patients.
COVID-19 is a rapidly evolving novel infectious disease caused by SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), leading to substantial morbidity and mortality. Due to its worldwide spread, immunocompromised patients, particularly those receiving B-cell depleting agents and who are unable to mount a specific humoral response to SARS-CoV2, may be at particular risk for a severe COVID-19 course (1, 2). In fact, repeated administration of rituximab (an anti-CD20 monoclonal antibody), is largely applied in the treatment of various B-cell malignancies and may lead to prolonged B-cell depletion and impaired production of total immunoglobulins (Ig) G and IgM (3, 4). Plasma provided by convalescent donors (i.e. convalescent plasma) has been proposed as a therapeutic option for COVID-19 (5), based on its partial effectiveness in other respiratory infections (6, 7). Consistent with this, several clinical trials have shown a benefit of convalescent plasma in COVID-19 patients with severe respiratory disease (8–10). It is likely that high anti-SARS-CoV2 IgG antibody levels (9, 10) are important for therapeutic effects. However, convalescent plasma may have additional and currently still unknown mechanisms of action (11).
This report presents the successful treatment of a severely immunocompromised patient with prolonged COVID-19 by four cycles of convalescent plasma transfusion. Our study provides insight into at least two distinct modes of action of plasma components. The first one may be related to its proposed anti-inflammatory activity. The second mechanism is mediated by SARS-CoV-2-specific IgG and neutralizing antibodies present in convalescent immune plasma, associated with progressive viral clearance, resulting in full clinical recovery from infection. Application of convalescent plasma with relative high titers of anti-SARS-CoV-2 antibodies represents a promising approach in the context of immunosuppressed patients with prolonged COVID-19 disease.
A 74-year-old man, in complete remission of a chronic lymphoid leukemia (CLL) after 6 cycles of rituximab and bendamustin (last therapy administrated in December 2019), presented to our emergency unit on April 1st 2020 with asthenia, loss of weight, dry cough and diarrhea since a month. He was otherwise healthy with well-controlled arterial hypertension and type 2 diabetes mellitus. SARS-CoV-2 RNA was detected (7x106 copies/ml) (12, 13) from a nasopharyngeal swab (defined as day 1). Laboratory analyses showed a moderate neutropenia, but severe T (114 cell/mm3) and B (1 cell/mm3) lymphopenia with reduced total immunoglobulin (Ig) G and IgM levels (Supplementary Figure 1A), while inflammatory markers (C-reactive protein and ferritin) were elevated (Figure 1A). Chest computed tomography (CT) revealed bilateral multifocal subpleural and peribronchial ground-glass opacities typical of COVID-19 pneumonia (14) (Figure 1B and Supplementary Figure 2). The clinical condition gradually deteriorated with sub-febrile episodes, persisting dry cough and diarrhea, and progressive weight loss and cognitive dysfunction (Figures 1C, D and Supplementary Information). Inflammatory parameters and blood cell counts remained abnormal (Figures 1A, E), while persisting SARS-CoV-2 infection was confirmed (Supplementary Figure 1B). Complementary investigations excluded other diagnoses (Supplementary Information). No specific antiviral agents were introduced given the mild symptoms of COVID-19 (e.g. absence of hypoxemia).
Figure 1 Clinical, biological and radiological follow-up before and after plasma transfusions. (A–E), Timeline of chronic SARS-COV-2 infection in a severely immunosuppressed patient showing inflammatory markers (A), chest CT scan (B), clinical parameters (C), MoCA (Montreal Cognitive Assessment) scores (D), and complete blood counts (E). (B), Axial slices focused at the level of the apical segment of the right lower lobe. Progressive worsening from multiple ill-defined areas of ground glass opacities progressing to patchy alveolar consolidation of increasing size. Note the subpleural (blue arrows) and peribronchial (orange arrows) distribution of the lesions with progressive improvement on post-therapeutic follow-up, alveolar consolidation being replaced by ground glass opacity. (A–E), Arrows indicate the 4 cycles of plasma transfusion (two units given on two consecutive days of each cycle). The “*” show the three injections of granulocyte-colony stimulating factor (filgrastim), while “T” indicates the two red blood cell transfusions. Of note, filgrastim injections (< day 40) and red blood cell transfusions did not result in symptom improvements.
In summary, the patient developed a long-lasting SARS-CoV-2 infection likely related to his severe immunosuppressive status. Consequently, we hypothesized that convalescent plasma could be beneficial in this particular case, by providing virus-specific neutralizing antibodies as well as a potential anti-inflammatory effect. Plasma units (3x200 ml/donor) were obtained from three selected donors, who had fully recovered from mild COVID-19 disease (Supplementary Information). Each donor presented relatively high IgG antibody titers against the S1 (spike)-protein using Euroimmun ELISA (15) (Supplementary Figure 3A). The first cycle of ABO-compatible plasma transfusion (two units on two consecutive days) was given on days 72 and 73 after diagnosis of SARS-CoV-2 infection, followed by three additional cycles, administered 10 to 15 days apart (Supplementary Figure 3A).
Rapid Improvement of Clinical, Inflammatory and Radiological Parameters Following Plasma Transfusion
Within the first eight days after the start of plasma transfusions, the patient improved clinically, biologically and radiologically (Figure 1). We observed a rapid normalization of the C-reactive protein, while absolute platelet counts and hemoglobin levels showed a more gradual return-to-normal. Follow-up chest CT scan confirmed a significant improvement in pulmonary infiltrates (Figure 1B and Supplementary Figure 2). Absolute lymphocyte counts also substantially improved (Figure 2A), and largely consisted of increased levels of memory-effector CD4 and CD8 T cells and of NK cells (by CyTOF multi-parametric mass cytometry (16); Supplementary Figure 4). Only a moderate rise was observed for total B cell counts (Figure 2B), mostly composed of unswitched memory B cells at day 121 (16); Supplementary Figure 4F), while total IgM and IgG remained globally stable (Supplementary Figure 1A). These data indicate clear improvements of inflammation, pneumonia and blood cell counts, already after the 1st cycle of convalescent plasma transfusion.
Figure 2 Anti-SARS-CoV-2 antibody and SARS-CoV-2 mRNA follow-up before and after plasma transfusions. (A, B), Timeline showing absolute CD4 and CD8 T cell counts, including effector-memory subsets and NK cell counts (A), and absolute B cell counts (B). (C, D), Anti-SARS-CoV-2 S protein IgG, IgA and IgM antibody levels as assessed by an in-house developed Luminex assay for each plasma (C) as well as in the patient’s serum before and following plasma transfusions (D). (E), Activity of neutralizing antibodies was assessed by a SARS-CoV-2 pseudovirus neutralization assay for each plasma and in patient’s serum at different time-points. (F), Over-time follow-up of SARS-CoV-2 RNA detection in nasopharyngeal swabs. The cytopathic effect on VeroE6 cells was evaluated after inoculation with SARS-CoV-2 from nasopharyngeal swabs: C+, successful virus isolation; C-, absence of virus isolation. (A–F), The arrows indicate the 4 cycles of plasma transfusion (two units given on two consecutive days of each cycle).
Cumulative Increase in Anti-SARS-CoV-2 IgG Titers Following Successive Plasma Transfusions
Most patients with COVID-19 develop SARS-CoV-2 IgM and IgG antibody responses within 19 days after symptom onset (17). To investigate whether such antibodies were transferred to our patient following successive cycles of plasma transfusion, we monitored the anti-SARS-CoV-2 S protein-specific IgG, IgA and IgM antibody levels by an in-house developed Luminex assay (18) (Supplementary Information). There was a remarkable heterogeneity among the three plasma donors, with plasma/donor 3 exhibiting highest levels of specific antibodies (Figure 2C and Supplementary Figure 3B). Whereas no anti-S IgG response was detected in the patient’s serum before the start of plasma transfusion, the antibody titers increased progressively, up to 30-fold over the baseline reference after the 4th cycle (Figure 2D and Supplementary Figure 3B). A similar trend, albeit at much lower levels, was found for anti-S IgA antibodies. Instead, anti-S IgM antibodies revealed two peaks following serial plasma transfusions (Figure 2D), again related to the level of specific-IgM antibodies of each plasma donor, with plasma/donor 3 showing highest titers (Figure 2C).
Temporal Association Between Detection of SARS-CoV-2 Neutralizing Antibodies and Viral Clearance
The activity of neutralizing antibodies was next measured by a SARS-CoV-2 pseudovirus neutralization assay in all three plasma as well as in patient’s serum before and after plasma transfusions (Supplementary Information; Supplementary Figure 3C). We further observed a boost of SARS-CoV-2 neutralizing activity after each cycle of plasma administration, in line with the higher antibody activity found in plasma/donor 3 when compared to the two others (Figure 2E). Importantly, this increase in SARS-CoV-2 neutralizing antibodies (Figure 2E) was inversely associated to the gradual decline observed in viral loads in nasopharyngeal swabs (Figure 2F), becoming undetectable for both E and RdRP genes (13) by day 111 of diagnosis.
To assess whether shedding of infectious SARS-CoV-2 still occurred after the start of plasma transfusions, we measured the presence of cultivable SARS-CoV-2 at different time-points (19) (Supplementary Information). While infectious virus could be isolated from nasopharyngeal swabs prior and following the 1st cycle of convalescent plasma transfusion, this was no longer the case upon the 2nd cycle (Figure 2F). Finally, the patient received one dose of intravenous immunoglobulin (IVIg; 0.4 g/kg) on day 114, providing additional passive immune protection against common pathogens, before being discharged from hospital (on day 115). He was considered as cured after two weeks of consecutive negative swabs (on day 127), but remaining potentially vulnerable to SARS-CoV-2 re-infection. The patient was followed initially by weekly and then monthly outpatient care. During this period, we observed an initial decline in anti-S IgG titers (18), followed by their subsequent stabilization over time (Supplementary Figure 3D). This was coincident to immune reconstitution, with the normalization of total B cell counts (Supplementary Figure 3D) and the appearance of naive B cells (16) (at day 203; Supplementary Figure 4F).
Collectively, our study offers novel evidence for a clear benefit of convalescent plasma in this particular case of COVID-19 disease, with the resolution of clinical, inflammatory and radiological parameters (Figure 1). Improvement of inflammation, pneumonia and blood cell counts preceded viral clearance. Importantly, this patient showed a temporal association between detection of SARS-CoV-2 neutralizing antibodies and virus clearance following successive cycles of plasma transfusion (Figure 2). Thus, our data provide insight into at least two distinct modes of action of plasma components. The first one is related to its proposed anti-inflammatory activity, similar to IVIg, widely used at high-dose for the treatment of several autoimmune diseases (11, 20). In this line, convalescent plasma therapy may help in modulating the immune response via F(ab’)2-dependent mechanisms including blockade of cell-cell interactions (via cell-surface receptors) and neutralization of cytokines, complement and autoantibodies (by anti-idiotypic antibodies). In addition, convalescent plasma activity might involve Fc-dependent pathways (e.g. modulation of Fcγ receptors on innate immune effector cells and B cells) (11, 20). A similar rapid anti-inflammatory effect was reported in a series of 17 consecutive patients with profound B-cell lymphopenia and prolonged COVID-19 infection, who were treated with 4 units of convalescent plasma (21). Specifically, Hueso and colleagues (21) observed a decrease in temperature and inflammatory parameters within a week, associated to oxygen weaning, while SARS-CoV-2 RNAemia decline occurred later, between 7 to 14 days after plasma transfusion.
Our observations support a second mechanism of action by SARS-CoV-2-specific IgG (18) and neutralizing antibodies present in convalescent immune plasma (Figure 2), which may mediate direct virus neutralization or other antibody-mediated pathways (e.g. complement activation, antibody-dependent cellular cytotoxicity). Passive antibody therapy has the great advantage to confer immediate immunity to vulnerable individuals (22). Interestingly, our data further suggest a relatively rapid effect of convalescent plasma with disappearance of cultivable SARS-CoV-2 readily after the second cycle of transfusion, despite intermediate levels of neutralizing antibodies and high RNA-positivity by qRT-PCR (Figure 2). This is in line with findings showing that neutralizing antibodies derived from COVID-19 patients may be effective, even at concentrations of 9 ng/ml or less (23). Strikingly, successive cycles of plasma transfusion (every 10-15 days) led to the cumulative increase in anti-S IgG titers, associated with a boost of neutralizing antibodies after each administration. Anti-S-specific IgM titers also followed a kinetic pattern related to the antibody levels of each transfused donor-plasma unit, indicating that a de novo endogenous antibody response was improbable at this stage. These observations are further in agreement with a recent report showing clinical resolution of COVID-19 following transfusion of convalescent plasma of high-titer neutralizing antibodies, in another case of humoral immunodeficiency (24). Finally, it is certainly possible that CD4 and CD8 T cells played critical roles (25) in the recovery of this patient who was primarily B cell deficient. This view is supported by reported cases of agammaglobulinemia patients who only presented mild COVID-19 disease (26).
Convalescent immune plasma therapy revealed stepwise anti-inflammatory and anti-SARS-CoV-2 effects, resulting in full clinical recovery from infection in a severely ill immunocompromised patient. Our data are in line with other studies (21, 24, 27, 28) reporting symptom resolution and clinical improvement following passive transfer of anti-SARS-CoV-2 antibodies through convalescent plasma in patients with immunodeficiency. Together, this therapeutic option can be considered as safe and represents a promising approach in the context of immunosuppressed patients with prolonged COVID-19 disease. At present, it remains to be seen how this compares to future monoclonal anti-SARS-CoV-2 antibodies and other novel COVID-19 therapies.
Data Availability Statement
The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding authors.
Ethical review and approval was not required for the study on human participants in accordance with the local legislation and institutional requirements. The patient/participants provided their written informed consent to participate in this study.
Study design and supervision: MMo, BG, DGa and NR. Patient care and acquisition of data: AZ, MMo, CB-A, DD, G-MS, DGe, MMe, PV, RS, MP, DC, BG and DGa. Development of methodology: CF, IE, CP, LI, and HA-U. Analysis and interpretation of data: AZ, CF, IE, CB-A, CP, KJ, DC, DGa and NR. Writing of the manuscript: AZ, DGa and NR. All authors contributed to the article and approved the submitted version.
This study was supported by the Lausanne University Hospital and University of Lausanne (Lausanne, Switzerland), and Interregional Blood Transfusion SRC (Lausanne, Switzerland).
Complementary clinical and methodological information for this case report can be found in the Supplementary Information.
Conflict of Interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
This manuscript has been released as a pre-print at Research Square, (Zimmerli et al. 29). We are grateful to patient A.P. and the blood donors for their dedicated collaboration in this study. We thank Drs. V. Aubert, W. Bosshard, M. Benazza, M. Caci Riedweg, E. Glampedakis, E. Jaquet, D. Samim, L. Senn, J.P. Simon, D. Solari, M. Touray, and the participating medical and laboratory teams of the Lausanne University Hospital (Lausanne, Switzerland) as well as the blood center teams of the Interregional Blood Transfusion SRC (Bern-Vaud-Valais, Switzerland) and the Regional Blood Transfusion Service (Basel, Switzerland). We thank Prof. G. Pantaleo for providing the technical platform for the pseudovirus neutralization assay. We are thankful to Dr. M. Essaidi-Laziosi and F. Pigny for their technical help and to Prof. Daniel E. Speiser and Dr. M. Prudent for comments and critical reading of the manuscript. Finally, we thank Prof. Gérard Waeber, head of the Department of Medicine, for his advice regarding patient care, as well as for his comments and critical reading of the manuscript.
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2021.613502/full#supplementary-material
1. Tepasse PR, Hafezi W, Lutz M, Kuhn J, Wilms C, Wiewrodt R, et al. Persisting SARS-CoV-2 Viraemia After Rituximab Therapy: Two Cases With Fatal Outcome and A Review of the Literature. Br J Haematol (2020) 190(2):185–8. doi: 10.1111/bjh.16896
2. Wood WA, Neuberg DS, Thompson JC, Tallman MS, Sekeres MA, Sehn LH, et al. Outcomes of Patients With Hematologic Malignancies and COVID-19: A Report from the ASH Research Collaborative Data Hub. Blood Adv (2020) 4(23):5966–75. doi: 10.1182/bloodadvances.2020003170
3. Worch J, Makarova O, Burkhardt B. Immunreconstitution and Infectious Complications After Rituximab Treatment in Children and Adolescents: What Do We Know and What Can We Learn from Adults? Cancers (Basel) (2015) 7(1):305–28. doi: 10.3390/cancers7010305
6. Mair-Jenkins J, Saavedra-Campos M, Baillie JK, Cleary P, Khaw FM, Lim WS, et al. The Effectiveness of Convalescent Plasma and Hyperimmune Immunoglobulin for the Treatment of Severe Acute Respiratory Infections of Viral Etiology: A Systematic Review and Exploratory Meta-Analysis. J Infect Dis (2015) 211(1):80–90. doi: 10.1093/infdis/jiu396
7. Tiberghien P, de Lamballerie X, Morel P, Gallian P, Lacombe K, Yazdanpanah Y. Collecting and Evaluating Convalescent Plasma for COVID-19 Treatment: Why and How? Vox Sang (2020) 115(6):488–94. doi: 10.1111/vox.12926
8. Li L, Zhang W, Hu Y, Tong X, Zheng S, Yang J, et al. Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial. JAMA (2020) 324(5):460–70. doi: 10.1001/jama.2020.12607
9. Libster R, Perez Marc G, Wappner D, Coviello S, Bianchi A, Braem V, et al. Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults. N Engl J Med (2021) 384(7):610–8. doi: 10.1056/NEJMoa2033700
10. Joyner MJ, Carter RE, Senefeld JW, Klassen SA, Mills JR, Johnson PW, et al. Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19. N Engl J Med (2021) 384(11):1015–27. doi: 10.1056/NEJMoa2031893
11. Rojas M, Rodriguez Y, Monsalve DM, Acosta-Ampudia Y, Camacho B, Gallo JE, et al. Convalescent Plasma in Covid-19: Possible Mechanisms of Action. Autoimmun Rev (2020) 19(7):102554. doi: 10.1016/j.autrev.2020.102554
12. Opota O, Brouillet R, Greub G, Jaton K. Comparison of SARS-CoV-2 RT-PCR on a High-Throughput Molecular Diagnostic Platform and the Cobas SARS-CoV-2 Test for the Diagnostic of COVID-19 on Various Clinical Samples. Pathog Dis (2020) 78(8):1–6. doi: 10.1093/femspd/ftaa061
15. Harvala H, Mehew J, Robb ML, Ijaz S, Dicks S, Patel M, et al. Convalescent Plasma Treatment for SARS-CoV-2 Infection: Analysis of the First 436 Donors in England, 22 April to 12 May 2020. Euro Surveill (2020) 25(28):1–7. doi: 10.2807/1560-7917.ES.2020.25.28.2001260
16. Leipold MD, Obermoser G, Fenwick C, Kleinstuber K, Rashidi N, McNevin JP, et al. Comparison of CyTOF Assays Across Sites: Results of a Six-Center Pilot Study. J Immunol Methods (2018) 453:37–43. doi: 10.1016/j.jim.2017.11.008
18. Fenwick C, Croxatto A, Coste AT, Pojer F, Andre C, Pellaton C, et al. Changes in SARS-CoV-2 Spike versus Nucleoprotein Antibody Responses Impact the Estimates of Infections in Population-Based Seroprevalence Studies. J Virol (2021) 95(3):1–12. doi: 10.1128/JVI.01828-20
19. L’Huillier AG, Torriani G, Pigny F, Kaiser L, Eckerle I. Culture-Competent SARS-CoV-2 in Nasopharynx of Symptomatic Neonates, Children, and Adolescents. Emerg Infect Dis (2020) 26(10):2494–97. doi: 10.3201/eid2610.202403
21. Hueso T, Pouderoux C, Pere H, Beaumont AL, Raillon LA, Ader F, et al. Convalescent Plasma Therapy for B-cell-depleted Patients With Protracted COVID-19. Blood (2020) 136(20):2290–5. doi: 10.1182/blood.2020008423
22. Bloch EM, Shoham S, Casadevall A, Sachais BS, Shaz B, Winters JL, et al. Deployment of Convalescent Plasma for the Prevention and Treatment of COVID-19. J Clin Invest (2020) 130(6):2757–65. doi: 10.1172/JCI138745
24. Honjo K, Russell RM, Li R, Liu W, Stoltz R, Tabengwa EM, et al. Convalescent Plasma-Mediated Resolution of COVID-19 in a Patient with Humoral Immunodeficiency. Cell Rep Med (2021) 2(1):100164. doi: 10.1016/j.xcrm.2020.100164
26. Quinti I, Lougaris V, Milito C, Cinetto F, Pecoraro A, Mezzaroma I, et al. A Possible Role for B Cells in COVID-19? Lesson from Patients With Agammaglobulinemia. J Allergy Clin Immunol (2020) 146(1):211–3.e4. doi: 10.1016/j.jaci.2020.04.013
27. Van Damme KFA, Tavernier S, Van Roy N, De Leeuw E, Declercq J, Bosteels C, et al. Case Report: Convalescent Plasma, a Targeted Therapy for Patients with CVID and Severe COVID-19. Front Immunol (2020) 11:596761. doi: 10.3389/fimmu.2020.596761
28. Tremblay D, Seah C, Schneider T, Bhalla S, Feld J, Naymagon L, et al. Convalescent Plasma for the Treatment of Severe COVID-19 Infection in Cancer Patients. Cancer Med (2020) 9(22):8571–8. doi: 10.1002/cam4.3457
Keywords: chronic SARS-CoV-2 infection, severe immunosuppression, B-cell depletion, convalescent plasma therapy, neutralizing antibodies, viral clearance
Citation: Zimmerli A, Monti M, Fenwick C, Eckerle I, Beigelman-Aubry C, Pellaton C, Jaton K, Dumas D, Stamm G-M, Infanti L, Andreu-Ullrich H, Germann D, Mean M, Vollenweider P, Stadelmann R, Prella M, Comte D, Guery B, Gachoud D and Rufer N (2021) Case Report: Stepwise Anti-Inflammatory and Anti-SARS-CoV-2 Effects Following Convalescent Plasma Therapy With Full Clinical Recovery. Front. Immunol. 12:613502. doi: 10.3389/fimmu.2021.613502
Received: 02 October 2020; Accepted: 01 April 2021;
Published: 21 April 2021.
Edited by:Jay Bream, Johns Hopkins University, United States
Reviewed by:Luis David Giavedoni, Texas Biomedical Research Institute, United States
Eliseo Albert, Hospital Clínico Universitario de Valencia, Spain
Copyright © 2021 Zimmerli, Monti, Fenwick, Eckerle, Beigelman-Aubry, Pellaton, Jaton, Dumas, Stamm, Infanti, Andreu-Ullrich, Germann, Mean, Vollenweider, Stadelmann, Prella, Comte, Guery, Gachoud and Rufer. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
†These authors have contributed equally to this work